Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease
Simon G Royce, Siddharth Rele, Brad RS Broughton, Kilian Kelly, Chrishan S Samuel
The FASEB Journal | FEDERATION AMER SOC EXP BIOL | Published : 2017
Awarded by National Health and Medical Research Council (NHMRC) of Australia
The authors acknowledge the facilities and technical assistance of Monash Histology Platform (Department of Anatomy and Developmental Biology, Monash University). This work was supported by a National Health and Medical Research Council (NHMRC) of Australia Senior Research Fellowship (GNT1041766) to C.S.S., and by Cynata Therapeutics funding to C.S.S. and S.G.R. S.G.R., S.R., B.R.S.B., and C.S.S. are with the Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University. S.G.R. is also affiliated with the Central Clinical School, Monash University. K.K. is an employee and shareholder of Cynata Therapeutics Ltd., but was not involved with performing the experiments or analysis of data.